Deals this week: Anthera Pharmaceuticals, Clearside Biomedical, G1 Therapeutics

9th March 2018 (Last Updated March 9th, 2018 00:00)

US-based biopharmaceutical company Anthera Pharmaceuticals Inc has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $100m through a public offering of shares of its common stock.

US-based biopharmaceutical company Anthera Pharmaceuticals has filed a registration statement with the Securities and Exchange Commission (SEC) to raise $100m through a public share offering of its common stock.

The company will issue a combination of common stock, preferred stock, warrants or units, as part of the transaction.

Anthera plans to use the proceeds towards clinical research and development and other general corporate needs including working capital and general administrative expenses.

The company has appointed Goodwin Procter as legal adviser for the transaction.

Clearside Biomedical has issued shares of its common stock through an underwritten public offering to raise $75m.

The underwriter will be granted a 30-day option to buy additional shares worth $11.25m.

The US-based biopharmaceutical company plans to use the proceeds for the submission of new application for its CLS-TA drug, which is used for the treatment of patients with non-infectious uveitis.

Part of the financing will also be used for the commercialisation and marketing of CLS-TA.

The company has selected Cooley LLP as the legal adviser for the transaction.

G1 Therapeutics has issued three million shares of its common stock priced at $24.13 a share in a public offering to raise $72.39m.

"Celgene will make an upfront payment of $101m and may extend the agreement by two more years, as well as make additional payments."

The underwriters will be granted a 30-day option to buy 450,000 additional shares.

The US-based healthcare company plans to utilise the proceeds for financing the development of trilaciclib, G1T38 and G1T48 as well as for general corporate needs.

The company has appointed J.P. Morgan Securities; Cowen and Company; Needham & Company; Wedbush Securities and BTIG as financial advisers, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo as legal advisers for the transaction.

CARsgen Therapeutics has secured $60m in a pre-series C financing round led by existing and new investors.

The Chinese clinical-stage immunotherapy company plans to use the proceeds towards investigational new drug (IND) submissions of CAR-T therapeutics.

Leap Therapeutics has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $100m through a public offering of shares of its common stock.

The US-based biopharmaceutical company plans to use the proceeds for general corporate purposes, including capital expenditures, working capital and other general expenses.

The company has appointed Morgan, Lewis & Bockius as legal adviser for the transaction.

Homology Medicines has filed a registration statement with the US Securities and Exchange Commission (SEC) for issuing shares of its common stock in a public offering to raise $100m.

The underwriters will be granted a 30-day option to buy additional shares by the company.

Homology is a US-based developer of gene therapy delivery platform for rare diseases.

The company plans to use the proceeds towards the pre-clinical and clinical development of its gene therapy product HMI-102, expansion of intellectual property portfolio, and ongoing R&D activities.

US-based cellular immunotherapy developer Unum Therapeutics plans to raise $86m through an initial public offering of shares of its common stock.

The company plans to use the proceeds for the phase one and phase two clinical development of ACTR087, ACTR707 and other product candidates.

Morgan Stanley, Cowen and Company, and Wedbush Securities have been appointed as underwriters, and Goodwin Procter as legal adviser for the transaction.

Vividion Therapeutics has signed a collaboration agreement with Celgene to use the former’s target discovery platform to develop small molecule drugs targeting oncology, inflammatory and neurodegenerative conditions.

Celgene will make an upfront payment of $101m and may extend the agreement by two more years, as well as make additional payments.

Both based in the US, Vividion is a biotechnology firm while Celgene is a biopharmaceutical company.